All IndicationsOphthalmologyPhase 3Phase 3Phase 2Phase 2
👁️
Uveitis
1
Companies
4
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
CLSD
Clearside Biomedical, Inc.
4 mg CLS-TA Suprachoriodal Injection
CLSD
Clearside Biomedical, Inc.
4mg CLS-TA Suprachoriodal Injection
CLSD
Clearside Biomedical, Inc.
0.8 mg CLS-TA
CLSD
Clearside Biomedical, Inc.
triamcinolone acetonide (Triesence®)
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| CLSD Clearside Biomedical, Inc. | 4 mg CLS-TA Suprachoriodal Injection | Phase 3 | — | — | — |
| CLSD Clearside Biomedical, Inc. | 4mg CLS-TA Suprachoriodal Injection | Phase 3 | — | — | — |
| CLSD Clearside Biomedical, Inc. | 0.8 mg CLS-TA | Phase 2 | — | — | — |
| CLSD Clearside Biomedical, Inc. | triamcinolone acetonide (Triesence®) | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
2
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.